SecProbe.io

CORRESP
1
filename1.htm

Wize Pharma, Inc.

24 Hanagar Street

Hod Hasharon, Israel 4527708

July 10, 2018

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

    Attn:
    Irene Paik, Christine Westbrook, Sasha Parikh and Sharon Blume

    Re:

        Wize Pharma, Inc.

        Registration Statement on Form S-1

        File No. 333-222889

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules
and Regulations under the Securities Act of 1933, as amended (the “Act”), Wize Pharma, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become
effective at 9:30 am, Eastern Time, on July 12, 2018, or as soon thereafter as possible.

The Company hereby
confirms that it is aware of its responsibilities under the Act, and the Securities Exchange Act of 1934, as amended, as they relate
to the proposed offering of the securities specified in the registration statement. The Company hereby acknowledges that:

1) should the Securities
and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to the filing;

2) the action of the
Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company
from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

3) the Company may
not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

    Very truly yours,

    /s/ OR EISENBERG

    Or Eisenberg

Acting Chief Executive Officer and

Chief Financial Officer

    Cc:

        Gregory Sichenzia, Esq.

        Avital Perlman, Esq.

        Ido Zemach, Adv.

        Yoni Henner, Adv.